BridgeBio Pharma receives FDA acceptance of NDA filing with priority review for oral infigratinib to treat achondroplasia

BridgeBio Pharma announced the FDA accepted its New Drug Application filing with Priority Review for oral infigratinib to treat achondroplasia in children, with a PDUFA date of February 4, 2027.

Detected & updated continuously · Source: Nebula